Mouhannad Jumaa, PhD

Senior Vice President, CMC and Non-clinical development

Mouhannad Jumaa worked with Perception since 2018 and joined the company full-time in 2021 with over 20 years of experience in the pharmaceutical industry.

After finishing postdoctoral studies in 2001, he worked as a senior scientist at 3M developing multiple novel formulations for inhalation and other administration routes. He worked at Rigel and Affymax, where he led the pharmaceutical development group, and he was a team member working on the development and approval of Omontys and Tavalisse.  In 2007, he joined Proteolix/Onyx and lead the pharmaceutical group. He led the CMC work, and co-invented the development of Kyprolis, which became a blockbuster treatment for refractory multiple myeloma.  After Amgen acquired Onyx, He co-founded Astura Therapeutics, a biotech start-up focusing on novel cancer therapies. He was responsible for all CMC, non-clinical and operation activities

In addition to operating roles, Mouhannad has served as an Adjunct assistant Professor in the Pharmaceutical Chemistry Department at University of Kansas and as member of the Scientific Advisory Committee of Journal of Pharmaceutical Science.

Mouhannad completed his BS degree in Pharmacy At Damascus University, and his Ph.D. degree in Pharmaceutical Science at Christian Albrechts University, Kiel/Germany. He completed his postdoctoral work in Pharmaceutical Chemistry working with National Cancer Institute working at KU.